Stockscreener 앱 받기
8.966
2.75%
-0.254
시간 외 거래:
9.40
0.434
+4.84%
전일 마감가:
$9.22
열려 있는:
$8.96
하루 거래량:
21,824
Relative Volume:
0.73
시가총액:
$245.58M
수익:
-
순이익/손실:
$-102.09M
주가수익비율:
-8.539
EPS:
-1.05
순현금흐름:
$-108.72M
1주 성능:
-7.09%
1개월 성능:
-7.76%
6개월 성능:
+101.94%
1년 성능:
+122.48%
1일 변동 폭
$8.80
$9.37
1주일 범위
$8.80
$9.6253
52주 변동 폭
$2.2045
$12.78
Dbv Technologies Adr Stock (DBVT) Company Profile
명칭
Dbv Technologies Adr
전화
33(0)155427878
주소
107 AVENUE DE LA REPUBLIQUE, CHATILLON
DBVT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
8.966 | 252.28M | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-29 | 재개 | Goldman | Sell |
| 2023-01-04 | 업그레이드 | Societe Generale | Hold → Buy |
| 2022-12-16 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-05-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-09-14 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-01-22 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2020-11-02 | 업그레이드 | Societe Generale | Sell → Hold |
| 2020-08-06 | 다운그레이드 | Societe Generale | Buy → Sell |
| 2020-08-05 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-17 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-01-09 | 업그레이드 | Stifel | Hold → Buy |
| 2019-12-16 | 개시 | Citigroup | Buy |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-06-17 | 개시 | Goldman | Buy |
| 2018-12-20 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-12-20 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2018-12-20 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-12-20 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-10-31 | 업그레이드 | Societe Generale | Sell → Hold |
| 2017-10-24 | 다운그레이드 | Societe Generale | Buy → Sell |
| 2017-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-06-23 | 개시 | Deutsche Bank | Buy |
| 2017-03-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2016-09-26 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-03 | 개시 | Barclays | Overweight |
| 2015-10-23 | 개시 | BofA/Merrill | Buy |
모두보기
Dbv Technologies Adr 주식(DBVT)의 최신 뉴스
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq - Placera.se
$150 Million Financing: DBV Technologies Launches New ATM Program to Fund VIASKIN Peanut Patch Development - Stock Titan
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire
Clinical-Stage Biotech DBV Technologies Featured at H.C. Wainwright Global Investment Conference - Stock Titan
Market reaction to DBV Technologies S.A. Depositary Receipt’s recent newsQuarterly Portfolio Review & High Conviction Trade Alerts - Newser
Should you hold or exit DBV Technologies S.A. Depositary Receipt nowJuly 2025 Opening Moves & Fast Entry and Exit Trade Plans - Newser
European ADRs End Lower As Healthcare And Telecom Diverge - Finimize
European ADRs: A Strategic Buy Amid Macroeconomic Shifts and Undervalued Sectors - AInvest
Will DBV Technologies S.A. Depositary Receipt continue its uptrendPortfolio Growth Summary & Long-Term Growth Stock Strategies - Newser
Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
European ADRs Climb On Solid Gains From Health And Tech Stocks - Finimize
Published on: 2025-08-19 16:04:03 - Newser
Using portfolio simulators with DBV Technologies S.A. Depositary Receipt includedQuarterly Profit Report & Daily Profit Focused Screening - Newser
DBV Technologies S.A. Depositary Receipt Moves Into Bullish Territory Based on MACD2025 Market Trends & Precise Swing Trade Alerts - metal.it
DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
European Biopharma ADRs: A Strategic Play in a Volatile Market - AInvest
Peanut Allergy Treatment Market Report 2025-2033, with Key Player Profiles for Aimmune Therapeutics, DBV Technologies, Sanofi, ALK-Abello, Prota Therapeutics, Camallergy, Aravax, and Genentech - Yahoo Finance
European ADRs Edge Higher While Sector Winners And Losers Diverge - Finimize
European ADRs Face Choppy Trading As Sentiment Sours - Finimize
Does DBV Technologies S.A. Depositary Receipt fit your quant trading modelAlpha Generation Strategy with Low Volatility - Newser
HC Wainwright Lowers Earnings Estimates for DBV Technologies - Defense World
DBV Technologies Maintains Buy Rating with €6.00 Target from Kepler Capital's Justine Telliez - AInvest
DBV Technologies Announces Filing of 2025 Half-Year Report - AInvest
DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report - GlobeNewswire
DBV Technologies S.A. - Via Ritzau
DBV Technologies Releases Latest Financial Report: Food Allergy Treatment Progress Updates Inside - Stock Titan
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results - GlobeNewswire
DBV Technologies Raises Massive $306.9M War Chest: Q2 Earnings Show Path to Viaskin Launch - Stock Titan
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - The Manila Times
DBV Technologies Liquidity Contract Update: Over €3M in Trading Volume Reveals Market Activity - Stock Titan
DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Tuesday - Defense World
DBV Technologies S.A. (NASDAQ:DBVT) Receives $14.75 Average PT from Analysts - Defense World
European ADRs Inch Higher As Drugmakers Shine - Finimize
DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer - The Manila Times
What analysts say about DBV Technologies S.A. Depositary Receipt stockHigh-impact stock picks - Autocar Professional
European Stocks In The US Finish With A Modest Rebound - Finimize
Analysts Are Bullish on Top Healthcare Stocks: Neurogene (NGNE), Cogent Biosciences (COGT) - The Globe and Mail
European ADRs Climb As Verona Pharma Leads Gains - Finimize
European ADRs Climb As Sequans Leads The Charge - Finimize
DBV Technologies’ SWOT analysis: peanut allergy patch stock poised for growth - Investing.com India
DBV Technologies (NASDAQ:DBVT) Upgraded to Hold at Wall Street Zen - Defense World
European Stocks Climb As ADRs Post Gains - Finimize
Dbv Technologies Adr (DBVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Dbv Technologies Adr 주식 (DBVT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer |
May 22 '25 |
Sale |
1.84 |
397 |
730 |
110,113 |
| Mohideen Pharis | Chief Medical Officer |
Jan 30 '25 |
Sale |
0.85 |
600 |
510 |
110,510 |
| Mohideen Pharis | Chief Medical Officer |
Nov 25 '24 |
Sale |
0.57 |
565 |
322 |
111,110 |
| Mohideen Pharis | Chief Medical Officer |
Nov 22 '24 |
Sale |
0.53 |
342 |
181 |
111,675 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '24 |
Sale |
0.54 |
2,350 |
1,269 |
112,017 |
1.40%
자본화:
|
볼륨(24시간):